

ALGA BIOLOGICS

Creation date : 01/11/2021

Sector of activity : Healthtech

TRL : 5

Development Phase : Industrialization



Activity

Inspired by the oceans, Alga Biologics offers a sustainable, innovative and cost-effective platform for the production of antibodies and recombinant proteins, using marine microalgae.

Co-founder information

Bardor Muriel, CEO/CSO : professor of Biochemistry and 2014 Junior Member of the Institut Universitaire de France, Muriel has __20 years of R&D experience in the production and characterization of antibodies and recombinant proteins in plants, mammalian cells and microalgae (Europe, Singapore and USA). A leading figure in biotechnology and biomanufacturing, she is known for her contributions to biopharmaceutical research. Muriel has coordinated a number of ambitious and innovative scientific projects and is a former deputy director of research laboratories where she published over 7 patents and 100 articles.

Gallot Catherine, Managing Director : with 25 years' experience in corporate management, business development and marketing in the medical device and industrial sectors, Catherine Gallot has managed interdisciplinary teams and developed commercial strategies in France and Europe.

Targeted Market

TAM : biomedicines market worldwide (€800B in 2030; CAGR 10.9%).

SAM : antibodies market estimate (€690B in 2030; CAGR 15.6%).

SOM : Alga Biologics aims to achieve international sales of €35M by 2030.

Next fundraising

Stage : Seed

Dilutive amount : €8 000 000

Non-Dilutive amount : €4 000 000

Fundraising objectives

Invest in additional photobioreactors, DSP and analytical equipments, implement the industrialisation up to 2000L, accelerate business development, reinforce the team and implement our technology in an environment that is GMP compliant with the pharmaceutical industry.

BHEALTHCARE

Creation date : 31/08/2016

Sector of activity : Healthtech

TRL : 7

Development Phase : Clinical trials

BHealthCare
L'INNOVATION DANS LE SANG

Activity

Bhealthcare is developing, industrializing and commercializing HEIVA, the all in one automatic blood collection platform.

Co-founder information

Aliaume Breteau-Hascouet, Chairman.

Jean-Baptiste de Chaisemartin, Managing Director.

Targeted Market

TAM : global blood collection market (\$31B in 2025).

SAM : global addressable blood collection market, excluding at home sampling (\$28B in 2025).

SOM : direct blood collection market for medical laboratories (\$13B in 2025).

Next fundraising

Stage : Pre-Series A

Dilutive amount : €5 000 000

Non-Dilutive amount : €0

Fundraising objectives

The fundraising aims to support conducting the last clinical trial, obtaining CE and UAE market approvals, and preparing for industrialization with partners.

BYOME LABS

Creation date : 06/12/2023

Sector of activity : Healthtech

TRL : 6

Development Phase : Industrialization



Activity

Helping brands to recommend the best products compatible with consumer's skin based on fast microbiome analysis.

Co-founder information

David Suissa, CEO : is an entrepreneur and expert in cosmetics, fragrances, and new technologies. He graduated from École Polytechnique and the French Corps des Mines, and is a former executive at the DGCCRF. In 2004, he founded and led Scentys, a startup specializing in airborne fragrance diffusion systems, until his exit in 2021. In 2022, he joined and managed BioFilm Control, a microbiology laboratory specializing in contract research for the pharmaceutical and cosmetic industries.

Stéphanie Badel Berchoux, CTO : holds an engineering degree in Biological Engineering from Polytech, complemented by a PhD in microbiology and biochemistry. She previously served as Laboratory Director at BioFilm Control, where she structured the microbiology department and oversaw client relations and scientific communication. At BYOME LABS, she leads the Clermont-Ferrand unit, managing client projects.

Margaux Jeanmougin, Marketing and Communications Director : is a communication and marketing professional with ten years of experience in the health and beauty industries. She previously served as Director of Digital Marketing and Communications for BIODERMA in North America, followed by roles in France and French Polynesia. She joined BYOME LABS as Marketing and Communications Director in 2023, bringing her expertise in project management and social media.

Targeted Market

TAM : global skin microbiome-based cosmetic market (\$31B by 2030).

SAM : brands and retailers integrating point-of-sale diagnostic technologies (\$6.2B by 2030).

SOM : early adopters of rapid microbiome testing technologies in Europe and North America (\$65M by 2030).

Next fundraising

Stage : Pre-seed

Dilutive amount : €1 800 000

Non-Dilutive amount : €0

Fundraising objectives

Byome Labs is preparing a fundraising round for Q2 2026 to support its international expansion and scale up innovation. This includes industrialization, commercial deployment, and further development of Byome Labs's AI-powered microbiome diagnostic platform.

LETSEE IMAGING

Creation date : 23/11/2023

Sector of activity : Healthtech

TRL : 4

Development Phase : POC



Activity

Letsee Imaging is developing a breakthrough mammograph, enabling the detection of all breast tumors at a very early stage, regardless of breast density. In France alone, our mammograph could save tens of thousands of lives and billions of euros a year in treatment costs.

Co-founder information

Ombeline de La Rochefoucauld, CEO : academic experience in medical research (6 years) and corporate X-ray imaging product development (7 years). HEC Challenge Plus graduate.

Philippe Zeitoun, CSO : director of Research at the CNRS. He was the first to transfer the Hartmann technique to X-rays 25 years ago (25 publications on Hartmann X-rays).

Targeted Market

TAM : global mammography market (\$4B in 2030).

SAM : European mammography market (\$1B in 2030).

SOM : French mammography market (\$200M in 2030).

Next fundraising

Stage : Pre-seed

Dilutive amount : €900 000

Non-Dilutive amount : €500 000

Fundraising objectives

The fundraising aims to recruit 6 people (2 IT specialists, 1 product engineer, 1 technician, 1 regulatory expert, 1 PhD student) to obtain the "First in human" images.

MAGIC GENOMIX

Creation date : 26/06/2023

Sector of activity : Healthtech

TRL : 5

Development Phase : Industrialization



Activity

Magic Genomix is developing a clinical decision tool for oncology for routine usage in hospital for early diagnosed patients before any oncology treatment.

Co-founder information

Frédéric Nahon, CEO : in charge of business development, fundraising and partnerships, as well as leading the team. Expert in the adoption of innovative solutions in HealthTech, with experience in iconic challenges with Pfizer Pharma and Intuitive Medtech.

Ataillah Benhaddou, CSO : co-inventor of the Magic patent with Inserm Toulouse, in charge of the development of new Magic iQ products for the search for new R&D signatures in drug discovery and drug repositioning.

Mohamed Ben Haddou, part time CTO : CEO of Mentis in Brussels, in charge of AI development for our Magic X software.

Patrick Kermaidic, part time CFO : in charge of organization and finance, has already set up 2 Fintech start-ups.

Targeted Market

TAM : cancer market for STM, Lung, Breast, Stomach and Ovaries (\$12B 2024).

SAM : market for new STM patients (\$192M in 2024).

SOM : Magic genomix hopes to achieve sales of \$5M from SAM by 2028.

Next fundraising

Stage : Pre-seed

Dilutive amount : €800 000

Non-Dilutive amount : €375 000

Fundraising objectives

The fundraising aims to set up a clinical study in soft sarcoma involving 4 French centers, develop and customize the software to analyze its interoperability, and continue the certification process for QMS and ISO 13485.

PERSEA

Creation date : 06/10/2021

Sector of activity : Healthtech

TRL : 4

Development Phase : Pre-clinical trials

Persea
Pharma

Activity

Persea is a French biotech developing BioTrojan, a Cell and Gene Therapy (CGT) revolutionizing solid cancer treatments: it destroys the tumor and prevents recurrence thanks to a vaccinating effect.

Co-founder information

Sophie de Ferrières, CEO : finance - HR - network - communication - corporate issues | 18-year sales & marketing and team management experience in the IT sector (Xerox, Samsung, HP) - Deputy director of Samsung printing division 2013-2017.

Gisèle Deblandre, CTO : in charge of the product development and industrialization | PhD, 25-year cellular therapy development, in both academic laboratory and industrial environment (MaSTherCell/Catalent, Cell'Easy).

Pr Olivier Pellerin, CMO : preclinical & clinical issues | MD, PhD, founder of the Oncologic Interventional Radiology unit in HEGP (APHP, Paris) - co-inventor of Persea patents.

Pr Marc Sapoval, Advisor : international exposure & KOL contacts | MD, PhD, head of the Interventional Radiology service in HEGP (APHP, Paris).

Targeted Market

TAM : global primary liver cancer drug market (\$40B in 2040).

SAM : US and European primary liver cancer stage B drug market (\$4B in 2040).

SOM : BioTrojan revenue generation (\$2.8B in 2040).

Next fundraising

Stage : Seed

Dilutive amount : €6 000 000

Non-Dilutive amount : €5 500 000

Fundraising objectives

The fundraising aims to support product development, enhance industrial property through in-house optimization, advance regulatory steps, and build a core team with key hires in R&D, quality, and regulatory roles.

SOQUT-IMAGING

Creation date : 15/11/2021

Sector of activity : Healthtech

TRL : 6

Development Phase : Clinical trials



Activity

SoQut-Imaging offers a medical imaging innovation developed from applied laboratory research, representing a breakthrough from current methods. : Liver tissue analysis using MRI.

Co-founder information

Benoit Chardonnet, CEO : is a Certified Accountant with 20 years of experience in accounting and audit. His extensive background in financial management makes him a key leader at the company.

Renaud Winzenrieth, Chief Clinical Officer : holds a PhD and has 25 years of experience in the medical device industry and regulatory affairs. His expertise ensures that the company meets all clinical and regulatory standards.

Simon Lambert and Benjamin Leporq, CSO : both hold PhDs and are researchers in physics and imaging. Their scientific knowledge and research skills drive the company's innovations in these fields.

Targeted Market

TAM : people affected by MASH (€125B in 2023).

SAM : monetization of liver MRI scans (€360M in 2023).

SOM : SoQut Imaging aims to address the US and European markets (€270M in 2023).

Next fundraising

Stage : Seed

Dilutive amount : €450 000

Non-Dilutive amount : €350 000

Fundraising objectives

Improve the MVP and initiate the regulatory phase.

SOUNDUCT

Creation date : 15/04/2021

Sector of activity : Healthtech

TRL : 7

Development Phase : Industrialization



Activity

Sounduct enables deaf people to recover hearing thanks to its patented dual bone conduction technology. By making people hear without going through the ear, Sounduct aims to revolutionize care of hearing pathologies, surpassing current solutions.

Co-founder information

Olivier Gauthier, Managing Director : with significant experience as a Business Developer for the health plans and wealth division at AXA, he has also held positions as Product Manager and Product Specialist at BNP Paribas Asset Management. Additionally, Olivier served as a Board Member of the French Federation for Silver Economy (Synapse), bringing valuable and diverse expertise to Sounduct's team.

Targeted Market

TAM : global market for hearing solutions including hearing aids, CROS, bone anchored, cochlear implants... (\$12B in 2024).

SAM : market/pathologies addressed by the Sounduct solution with +20 million devices per year (\$10B in 2024).

SOM : targeted market to cover patients with fitting failure or suffering from pathologies without any solution, or to substitute some implants, CROS... (\$1B in 2024).

Next fundraising

Stage : Series A

Dilutive amount : €5 000 000

Non-Dilutive amount : €5 000 000

Fundraising objectives

The fundraising aims to support market launch and industrialization.

SURGITEC ROBOTICS

Creation date : 15/12/2023

Sector of activity : Healthtech

TRL : 5

Development Phase : Pre-clinical trials



Activity

Surgitec Robotics designs a next-gen surgical robot for hard-tissue procedures, combining affordability, versatility, and simplicity to enable widespread adoption of robotic-assisted surgery.

Co-founder information

Laure Caucanas, CEO : she brings over 20 years of experience in structured financial solutions and strategic advisory, with a clear entrepreneurial drive. Her track record includes leading roles in finance and consulting for high-tech and innovation-driven sectors. She provides the vision and execution capacity required to build and scale a medtech startup, aligning financial strategy with technical development.

Michel Lefranc, CSO : professor of Neurosurgery with over 20 years of international recognition in surgical robotics. Michel was a major contributor to the design of the ROSA robot, a widely adopted neurosurgical platform, and he is the founder of GRECO, the first research institute dedicated to robotic surgery. His academic authority and innovation leadership ensure strong clinical relevance and credibility for Surgitec's technology development.

Florian Coiseur, CTO : he has more than 15 years of experience in surgical robotics. He previously served as Head of IP and Innovation at ZimmerBiomet and has held key roles across the entire product lifecycle in leading R&D teams. His deep technical and industrial expertise enables Surgitec to design and execute a robust, clinically adapted, and scalable robotic platform.

Targeted Market

TAM : global surgical robotics market (\$100B by 2035).

SAM : hard-tissue robotic surgery market in Europe and North America (\$20B by 2035).

SOM : realistic early market penetration by Surgitec Robotics (\$2B by 2035).

Next fundraising

Stage : Seed

Dilutive amount : €4 000 000

Non-Dilutive amount : €0

Fundraising objectives

Secure the resources needed to reach a major milestone : conducting the first-in-human clinical trial by the end of 2026.

THERASONIC

Creation date : 16/11/2023

Sector of activity : Healthtech

TRL : 5

Development Phase : Pre-clinical trials



Activity

TheraSonic is a MedTech startup whose ambition is to transform the management of neurological diseases. It is developing the first medical robot to increase the local brain concentration of drugs in the brain, quickly, precisely and non-invasively using focused ultrasound.

Co-founder information

Benoit Larrat, CEO : ESPCI engineer, PhD in Physics, HEC challenge+ (one year entrepreneurship training program). Former researcher at CEA on the technology for 14 years. Co-author of 40+ publications of relevance in the field, co-inventor of 3 patent families, worldwide reknown expert in medical imaging and neurotechnologies. Benoit has the global vision and has led the project since its birth in academic projects. He is finding and managing the resources needed to transform prototypes into commercial products and validate them through clinical trials.

Anthony Novell, CSO : PhD in Physics, researcher director at CNRS. co-author of 55+ publications in medical acoustics, co-inventor of 4 patent families. Anthony pursues the development of the technology and drives the partnership with industrial and academic partners through collaborative projects.

Targeted Market

TAM : drug treatment of brain metastasis (€3B/y in 2030; 8% CAGR).

SAM : brain mets in Europe and North America (€1.2B in 2030).

SOM : 10% of brain mets patients in expert centers (€350M/y by 2030).

Next fundraising

Stage : Seed

Dilutive amount : €5 000 000

Non-Dilutive amount : €2 000 000

Fundraising objectives

The fundraising aims to complete the development of the commercial version of the medical device, deploy an ISO 13485 quality management system, and set up the regulatory and clinical files for a multicentric pilot clinical study by 2027.